Market Cap 32.22M
Revenue (ttm) 640,000.00
Net Income (ttm) -69.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,921.88%
Debt to Equity Ratio -1.15
Volume 577,100
Avg Vol 1,883,844
Day's Range N/A - N/A
Shares Out 27.08M
Stochastic %K 24%
Beta 0.31
Analysts Strong Sell
Price Target $14.60

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 475-238-6837
Address:
555 Long Wharf Drive, 12th Floor, New Haven, United States
Xhysh
Xhysh May. 15 at 9:35 PM
$BTAI This is a big one, guys. From their own corporate update Strategic Options Exploring Value-Maximizing Options: The Company engaged MTS Health Partners as an advisor for evaluation of strategic options to maximize shareholder value and advance the commercial and development plans for IGALMI, which may include, but are not limited to, a sale of the Company, a merger or other business combination, a collaboration, joint venture, royalty or license agreement of all or a portion of our assets, a recapitalization or other financing transaction, or continued execution of our standalone operating plan. We have not made a decision to pursue any specific transaction or strategic option, no set timetable has been established for the completion of this process, and there can be no assurance that the process will result in any transaction or other particular outcome. Aka, they finally realize they can't commercialize this and are finally ready to just sell it to someone who can
0 · Reply
TornadoChasers
TornadoChasers May. 15 at 5:46 PM
$BTAI Lets see a nice rally here!
0 · Reply
SrTxan
SrTxan May. 15 at 3:35 PM
$BTAI The 2M shares from the recent offering have now officially appeared. Armistice Capital is reporting ownership of 1,910,076 shares, which equals approximately 7.05% of the company. Interesting part? They didn’t flip the shares immediately after the offering. They’re still sitting on a sizeable position while BTAI is trading near uncertainty lows. Funds like Armistice don’t usually take a 7% position in a biotech unless they see a much bigger upside opportunity ahead. With the at-home IGALMI PDUFA now set for Nov. 14, 2026, the setup is getting very interesting.
2 · Reply
igniteyourpassion
igniteyourpassion May. 15 at 3:24 PM
$BTAI back to under 1, then dilute rinse repeat and feed the higher levels above
0 · Reply
modernaproblema
modernaproblema May. 15 at 2:47 PM
$BTAI just being patient averaging down…
0 · Reply
Merlintrader
Merlintrader May. 15 at 2:06 PM
$ATYR Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates https://www.merlintrader.com/regulatory-paths-updates-may2026/
0 · Reply
BayAreaBiotech
BayAreaBiotech May. 15 at 11:55 AM
$BTAI Interesting move by BioXcel Therapeutics hiring MTS Health Partners. Historically, biotech companies bring in firms like MTS during major strategic turning points, such as partnerships, commercialization planning, financing, or potential M&A discussions. For BTAI, this likely signals they’re exploring ways to strengthen the balance sheet and maximize the value of the IGALMI at-home opportunity ahead of the upcoming regulatory catalyst.
1 · Reply
focafoca99
focafoca99 May. 15 at 11:26 AM
$BTAI released its Q1 2026 financial results and business update.
1 · Reply
sleighbell
sleighbell May. 15 at 12:00 AM
$BTAI idk if this helps but they beat earnings, I don't see any PRs for it yet.
3 · Reply
Longtermlooker
Longtermlooker May. 14 at 6:42 PM
0 · Reply
Latest News on BTAI
BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)

2026-05-15T12:03:32.000Z - 12 hours ago

BioXcel Therapeutics reports Q1 EPS (54c), consensus (49c)


BioXcel Therapeutics Transcript: Investor update

Apr 23, 2026, 2:00 PM EDT - 22 days ago

BioXcel Therapeutics Transcript: Investor update


BioXcel Therapeutics enrolls first patients in BXCL501 trial

2026-04-08T11:09:11.000Z - 5 weeks ago

BioXcel Therapeutics enrolls first patients in BXCL501 trial


BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

2026-04-01T11:09:26.000Z - 6 weeks ago

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA


BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

2026-03-27T11:20:13.000Z - 7 weeks ago

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)


BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw

2026-03-17T12:06:20.000Z - 2 months ago

BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw


BioXcel price target lowered to $6 from $10 at H.C. Wainwright

2026-03-05T13:59:23.000Z - 2 months ago

BioXcel price target lowered to $6 from $10 at H.C. Wainwright


BioXcel Therapeutics Transcript: Status update

Feb 27, 2026, 2:00 PM EST - 2 months ago

BioXcel Therapeutics Transcript: Status update


BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

2026-01-20T12:06:39.000Z - 4 months ago

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi


BioXcel Therapeutics appoints Pavao as acting CCO

2026-01-12T12:21:09.000Z - 4 months ago

BioXcel Therapeutics appoints Pavao as acting CCO


BioXcel Therapeutics Transcript: AGM 2025

Dec 12, 2025, 9:00 AM EST - 5 months ago

BioXcel Therapeutics Transcript: AGM 2025


BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

2025-11-12T12:16:09.000Z - 6 months ago

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)


BioXcel Therapeutics regains compliance with Nasdaq

2025-09-18T11:11:17.000Z - 8 months ago

BioXcel Therapeutics regains compliance with Nasdaq


BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 2:00 PM EDT - 8 months ago

BioXcel Therapeutics Transcript: Study Result


BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 8:00 AM EDT - 9 months ago

BioXcel Therapeutics Transcript: Study Update


BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:29 AM EDT - 9 months ago

BioXcel's agitation drug meets main goal in at-home study


BioXcel Therapeutics Announces Reverse Stock Split

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split


BioXcel Therapeutics Announces Proposed Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering


BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024


BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference


Xhysh
Xhysh May. 15 at 9:35 PM
$BTAI This is a big one, guys. From their own corporate update Strategic Options Exploring Value-Maximizing Options: The Company engaged MTS Health Partners as an advisor for evaluation of strategic options to maximize shareholder value and advance the commercial and development plans for IGALMI, which may include, but are not limited to, a sale of the Company, a merger or other business combination, a collaboration, joint venture, royalty or license agreement of all or a portion of our assets, a recapitalization or other financing transaction, or continued execution of our standalone operating plan. We have not made a decision to pursue any specific transaction or strategic option, no set timetable has been established for the completion of this process, and there can be no assurance that the process will result in any transaction or other particular outcome. Aka, they finally realize they can't commercialize this and are finally ready to just sell it to someone who can
0 · Reply
TornadoChasers
TornadoChasers May. 15 at 5:46 PM
$BTAI Lets see a nice rally here!
0 · Reply
SrTxan
SrTxan May. 15 at 3:35 PM
$BTAI The 2M shares from the recent offering have now officially appeared. Armistice Capital is reporting ownership of 1,910,076 shares, which equals approximately 7.05% of the company. Interesting part? They didn’t flip the shares immediately after the offering. They’re still sitting on a sizeable position while BTAI is trading near uncertainty lows. Funds like Armistice don’t usually take a 7% position in a biotech unless they see a much bigger upside opportunity ahead. With the at-home IGALMI PDUFA now set for Nov. 14, 2026, the setup is getting very interesting.
2 · Reply
igniteyourpassion
igniteyourpassion May. 15 at 3:24 PM
$BTAI back to under 1, then dilute rinse repeat and feed the higher levels above
0 · Reply
modernaproblema
modernaproblema May. 15 at 2:47 PM
$BTAI just being patient averaging down…
0 · Reply
Merlintrader
Merlintrader May. 15 at 2:06 PM
$ATYR Regulatory Paths, PDUFA Risk and Pivotal Oncology: $ATYR, $BTAI and $MBRX After the May 15 Updates https://www.merlintrader.com/regulatory-paths-updates-may2026/
0 · Reply
BayAreaBiotech
BayAreaBiotech May. 15 at 11:55 AM
$BTAI Interesting move by BioXcel Therapeutics hiring MTS Health Partners. Historically, biotech companies bring in firms like MTS during major strategic turning points, such as partnerships, commercialization planning, financing, or potential M&A discussions. For BTAI, this likely signals they’re exploring ways to strengthen the balance sheet and maximize the value of the IGALMI at-home opportunity ahead of the upcoming regulatory catalyst.
1 · Reply
focafoca99
focafoca99 May. 15 at 11:26 AM
$BTAI released its Q1 2026 financial results and business update.
1 · Reply
sleighbell
sleighbell May. 15 at 12:00 AM
$BTAI idk if this helps but they beat earnings, I don't see any PRs for it yet.
3 · Reply
Longtermlooker
Longtermlooker May. 14 at 6:42 PM
0 · Reply
BioSpecialOne
BioSpecialOne May. 14 at 2:34 PM
0 · Reply
CoffeeRocks
CoffeeRocks May. 14 at 11:10 AM
0 · Reply
BurntReynolds
BurntReynolds May. 13 at 10:25 PM
0 · Reply
CoffeeRocks
CoffeeRocks May. 13 at 5:27 PM
$TRAW Another good entry $BTAI $CODX $CNTN
0 · Reply
wndyctyboy1975
wndyctyboy1975 May. 13 at 2:01 AM
$BTAI pretty soon back to 1.05?
0 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 12:29 PM
1 · Reply
CoffeeRocks
CoffeeRocks May. 12 at 11:09 AM
0 · Reply
CoffeeRocks
CoffeeRocks May. 11 at 7:36 PM
$BTAI $ACAD https://finance.yahoo.com/markets/stocks/articles/earnings-miss-acadia-pharmaceuticals-inc-112731765.html
0 · Reply
wndyctyboy1975
wndyctyboy1975 May. 11 at 4:48 PM
$BTAI maybe one day it will go up like it fell
0 · Reply
CoffeeRocks
CoffeeRocks May. 11 at 2:26 PM
$CODX $VRAX $BTAI $PGEN $THC 1.5$-2.6$ not bad not bad
1 · Reply
CoffeeRocks
CoffeeRocks May. 11 at 2:17 PM
$BTAI $CODX $INHD $INO $PGEN Let’s get IT!!!!!
0 · Reply
CoffeeRocks
CoffeeRocks May. 11 at 11:39 AM
$BTAI $CODX $INHD $INO $PGEN Picks CODX fda approval at home tests BTAI earnings waiting for approval at 🏡 test INO earnings PGEN earnings
1 · Reply